Question 1

Why does this page name no seller?

Accepted Answer

The query behind this page is a request for a name, and a name is the one thing it will not hand over. We publish no rankings, no scores and no recommended sellers, and placement on this site has never been available for purchase. That is a standing editorial position, but it also follows directly from the evidence. Among the sources behind this page, not one sets two sellers beside each other and measures them on any property a buyer could act on. A 2026 review in Sports Med describes a gray market of unapproved compounds that has emerged, operating largely outside of regulatory oversight. That is a description of a market rather than a verdict on the individual firms operating inside it. A name would be the easiest thing to publish here and much the hardest to stand behind, because it would ultimately rest on reputation. Reputation is not a checkable fact about anybody. What can be checked is the documentation attached to one particular vial, together with the public record attached to the firm whose address appears on it.

Question 2

How do you tell whether a supplier is legitimate?

Accepted Answer

You cannot tell from the website, because every signal a seller controls is written by the party you are checking. A laboratory logo, a purity figure, a years-in-business line and a wall of reviews are assertions in one voice. Four things sit outside that voice. A certificate of analysis names a laboratory, and that laboratory can be contacted directly and asked whether it issued the document for that particular batch. A trading name can be searched on a public company register, which returns an entity, a jurisdiction and a status, or returns nothing at all. The FDA enforcement database can be searched for the firm and for the compound, and searching it is free. A street address on a recall entry can be set against the address a seller gives. A 2026 review names the condition all four checks are working around: the uncertainty surrounding product composition, dose, and stacking practices in unregulated supply chains. None of the four demonstrates that a vial holds what its label says. Together they establish only whether anybody outside the business has ever written anything down.

Question 3

Why does a laboratory report cover a batch rather than a seller?

Accepted Answer

A certificate of analysis covers one sample drawn from one batch on a single date, and that sentence contains every limitation worth knowing. It can report what a laboratory found in the material it was handed, which is why the batch or lot number printed on the document has to match the number on the vial in front of you. It establishes nothing about the next batch, about a batch produced after the report was issued, or about how the vial was handled on its way to your door. A certificate also cannot vouch for itself, because it is a file, and a file can be edited, reused across batches, or written by nobody in particular. The step that converts it from a graphic into evidence is contacting the laboratory named on it and asking whether the report is genuinely theirs. So a certificate is evidence about material and never evidence about a company. A seller publishing a hundred of them has demonstrated a hundred batches rather than a standard. The same document read against a single molecule is worked through at the BPC-157 sourcing page.

Question 4

What turned up when products sold online were analysed?

Accepted Answer

Two investigations have purchased this kind of material and measured what was inside it, which is as close to a direct answer as these sources come. In a 2017 JAMA analysis of 44 products sold through the internet, only 23, or 52 per cent, held one or more of the compounds the listings named. The same analysis found that no active compound was detected in 4 of the 44, and that substances not listed on the label were present in 11. The labelled amount matched the measured amount in 18 of the 44, which is 41 per cent. Those were selective androgen receptor modulators rather than peptides, so the figures do not transfer to a peptide vial, and nothing in these sources repeats the exercise on one. What does transfer is the method, together with one uncomfortable fact: in the only sample anybody measured, the label was wrong more often than it was right. A European market surveillance study later reported in total 324 samples and 354 results, from 14 laboratories in 13 countries, most of them from illegal distribution.

Question 5

Is purity the same question as identity?

Accepted Answer

These are two different questions, and a certificate often answers only one. Identity asks whether the molecule in the vial is the one named on the label. Purity asks how much of what is in there is that molecule. A sample can be 99 per cent pure and still be the wrong thing entirely. A purity figure with no identity method has answered the second question and left the first one open. The 2017 JAMA work kept the two apart. It reports that the identities of the compounds and their amounts were determined from April to August 2016 using chain-of-custody and World Anti-Doping Association-approved analytical procedures. Naming a molecule is not quick work either. A 2018 review of falsified biotech medicines says laboratories often have to resort to a combination of electrophoretic techniques, immunological assays and mass spectrometry based approaches to merely identify the content of seized samples. If a national laboratory needs three methods to name a molecule, one number on a web page is not the same kind of statement.

Question 6

What has been documented about falsified peptide products?

Accepted Answer

Fakes in this category are documented rather than rumoured, and the record is specific about the shapes they take. A 2018 review says that multiple reports have described the presence of the wrong active pharmaceutical ingredient, the wrong dosage or the absence of the API. The same review adds that unauthorized polypeptides or polypeptides which failed clinical trials or are still subject of clinical or pre-clinical assessments have been found in seizures of regulatory agencies. It names two of the molecules covered on this site: human growth hormone and melanotan II. The European survey adds how the material was dressed up. Sixty-five percent of the seized products were represented as medicine, though 24% as dietary supplements. That gap matters to a buyer, because the two framings set different expectations and the material underneath was the same material. None of this is a finding about any one seller, and it is not offered as one.

Question 7

What do the FDA enforcement entries actually fault?

Accepted Answer

Thirty-seven enforcement entries sit behind this page, covering six different compounds between 2012 and 2026, and read together they establish something no single compound page can. Twenty-three of the 37 fault sterility, in the wording lack of assurance of sterility or lack of sterility assurance. Five fault processing controls, and four concern a delivery device rather than a vial. One records a label mix-up, one a chemical contamination, one a temperature excursion during shipping, and one a failure to finish process validation before distribution. Exactly one of the 37 is about how much compound was actually in the vial, filed in July 2025 as a Subpotent Drug. A recall is almost always a finding about the premises and the process, rather than about the molecule or about whether it does anything at all. A 2025 entry for a BPC-157 injection gives its reason as Lack of Assurance of Sterility. A 2022 entry spells the identical finding out as deviations from Current Good Manufacturing Practices (CGMP) that call into question the sterility of products intended to be sterile. How to search this database for a single compound is laid out at the Retatrutide sourcing page.

Question 8

Who do the enforcement records name?

Accepted Answer

Every one of the 37 entries behind this page names a business, usually with a street address, and not one of them names a buyer. A 2019 entry reads BPC 157, 10mg injection, Rx Only, Promise Pharmacy Compounding Specialists, followed by an address in Palm Harbor, Florida. A 2014 somatropin entry names a Teva division in Sellersville, Pennsylvania, and records that the vials may contain silicone oil due to leakage of a leaking line during the freeze-drying process. A 2025 Wegovy entry names a shipping error involving a Cardinal Health distribution center rather than a manufacturer at all. This is worth stating plainly, because the familiar legal worry about buying is really a worry about personal consequences. The enforcement record is a register of actions taken against firms, so it establishes what regulators have done to sellers and says nothing whatever about anybody who ordered from one. We are not lawyers and this is not legal advice; it is a description of what that register contains.

Question 9

Which of these compounds has an approved version at all?

Accepted Answer

This split decides what every other question on the page means. A few of these molecules exist as approved prescription products with a label filed at a regulator. A 2022 review records that trial results led to Food and Drug Administration approval of Wegovy (semaglutide) for weight loss. Another records that lonapegsomatropin received its first approval in August 2021 in the USA for pediatric patients at least 1 year of age. Most of them do not. A 2026 review states that most of these therapies remain unapproved by the U.S. Food and Drug Administration (FDA) and clinical evidence in humans is limited. A 2025 review of BPC-157 says the same for a single compound: it has not been approved for use in standard medicine by the FDA and other global regulatory authorities. The practical consequence is that an approved label belongs to the approved product and to nothing else. A compounded or research-grade vial carrying the same chemical name has no label, no filed specification and no approved indication, however closely the name matches.

Question 10

Is it legal to buy peptides?

Accepted Answer

This is several different questions wearing a single coat, and the useful version of the answer pulls them apart. Approval status is a regulatory fact and it is already on the record: most of these therapies remain unapproved by the U.S. Food and Drug Administration, while a few exist as approved prescription products. Marketing status is a second fact, and the enforcement entries behind this page show regulators acting against firms that compounded and distributed these molecules. Prescription status is a third. The recall titles themselves carry the words Rx Only and Prescription Only on compounded BPC-157, melanotan II and somatropin alike. Whether a particular purchase in a particular country breaks a particular law is a fourth question entirely. It turns on jurisdiction, quantity, presentation and intent, and no page can settle that for a reader. So we report what the regulatory record says and stop at that point, because a yes or a no is the one thing here that somebody might actually act on. The position for single compounds is written up at the Melanotan sourcing page and the MK-677 sourcing page.

Question 11

Do you need a prescription to order peptides?

Accepted Answer

For the approved molecules the answer is printed on the carton and visible in the database, where somatropin, semaglutide and tirzepatide entries are marked Rx only repeatedly. One 2026 tirzepatide entry describes a Sterile Multi-Dose Vial, Rx only, held by a named firm. For the unapproved compounds the question dissolves, because a prescription is written against an approved indication and these molecules have none. That is why the same compound can reach a buyer through a compounding pharmacy on a prescriber's order, and through a website with no prescriber involved anywhere. The two routes leave completely different paper trails. The first leaves a named pharmacy, a licence, and an entry in the enforcement database whenever something goes wrong. The second leaves a payment and a parcel. Which of the two you are dealing with is usually obvious from whether anybody asked for a prescriber's name, and it is worth establishing before the remaining checks are worth running.

Question 12

What is a compounding pharmacy, and where does it sit?

Accepted Answer

A compounding pharmacy prepares a medicine to order rather than manufacturing a filed, approved product, and it occupies the ground between the pharmacy counter and the open internet. It is a real, licensed category. The 2024 bladder-pain pilot set out to assess the safety and efficacy of BPC-157 manufactured by a 503A compounding pharmacy, which is the clearest documented case of a research compound reaching patients by a regulated route. It is also where a large share of the enforcement record lives, because a compounder filling sterile injections can be inspected and can fail that inspection. That is the trade a buyer is actually making. A compounded vial comes with a named premises that a regulator can visit. It also comes with no approved label, no filed specification, and no connection to any trial material. Both halves are true at once, and reading only one of them is how this category gets misunderstood. The compounded and approved split is worked through for single molecules at the Semaglutide sourcing page and the Tirzepatide sourcing page.

Question 13

Are peptides easy to buy?

Accepted Answer

The published sources treat easy access as the normal state of this category rather than as news. A 2025 review in Arthroscopy says these compounds are unregulated and yet readily available for purchase over the internet, and that there is scarce orthopaedic literature investigating the clinical use and outcomes of such therapeutic peptides. A 2026 review describes the agents most commonly encountered in clinical practice and online self-administration protocols, which is a clinician reporting what walks into a consulting room. The gap inside those two sentences is the buyer's whole problem. Access is easy and information about what was accessed is thin. So the effort that would otherwise go into choosing between sellers has nowhere useful to land, while effort spent checking one batch and one firm does. It is also why the order of work here runs outward from documents and registers, rather than inward from reputation.

Question 14

What does the vendor index on this site record?

Accepted Answer

There is a record for each of 128 sellers at the vendor records, and the first thing to say about it is that no record currently carries a finding. Five checks are defined: how many listed items carry a certificate a buyer can read before paying, whether the named laboratory confirms issuing it, whether a matching entity appears on a public company register, whether the FDA databases hold warning letters or recalls naming the business, and the date a person last ran all four. None of them has been carried out yet, so the index is a list of names and a stated method rather than a set of results. It is not a ranking, the order never reflects quality, and a row reading none found would mean only that a search returned nothing on the day it was run. An absence in a public database is an absence, and reading it as a clean record is precisely the mistake the whole index is built to avoid.

Buying peptides online